This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
targeted-therapy
Targeted Therapy
Small molecules or antibodies targeting specific oncoproteins driving tumor growth: kinase inhibitors (imatinib/BCR-ABL, erlotinib/EGFR, vemurafenib/BRAF), HER2 inhibitors (trastuzumab), VEGF inhibitors (bevacizumab). Exploits oncogene addiction.
Entry Metadata
| Field | Value |
|---|---|
| ID | targeted-therapy |
| Name | Targeted Therapy |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Stream | 01-modern |
| Drug class | targeted antineoplastic |
Cross-Atlas Connections
Sources
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7. · PubMed 11287972
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. · PubMed 11248153
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39. · PubMed 15118073